| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $133.7M | +18.9% |
| SG&A Expense | $36.1M | +19.8% |
| Operating Income | -$169.8M | -19.1% |
| Income Tax | $0 | — |
| Net Income | -$161.3M | -26.5% |
| EPS (Basic) | -$3.64 | -9.3% |
| EPS (Diluted) | -$3.64 | -9.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $124.1M | +28.4% |
| Short-term Investments | $155.2M | -18.1% |
| Current Assets | $283.0M | -2.6% |
| Total Assets | $293.8M | -3.6% |
| Current Liabilities | $36.5M | +8.1% |
| Total Liabilities | $61.5M | +61.7% |
| Stockholders' Equity | $232.3M | -12.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$153.7M | -34.5% |
| Capital Expenditures | $5K | -99.8% |
| Investing Cash Flow | $40.0M | +124.9% |
| Financing Cash Flow | $141.2M | -58.1% |
| Free Cash Flow | -$153.7M | -32.0% |